Emergent BioSolutions (EBS) Stock Analysis & Winston Score

Emergent BioSolutions makes vaccines and medicines that protect people from biological threats like anthrax, smallpox, and opioid overdoses. Its most well-known products include BioThrax, the only FDA-approved anthrax vaccine in the United States, and Narcan, a nasal spray that reverses opioid overdoses. The company's main customers are government agencies, including the U.S. Department of Defense and the Strategic National Stockpile. Emergent earns most of its revenue by selling these products directly to governments under long-term contracts, which provides some stability but also heavy dependence on a small number of buyers. The company operates primarily in the United States and also offers contract manufacturing services to other drugmakers. Emergent has faced serious challenges in recent years, including manufacturing problems and the loss of key contracts, which contributed to its negative return on invested capital and a much smaller business than it once was. Its ability to win new government contracts and stabilize its manufacturing operations will determine whether the company can recover.